Lilly and Boehringer say Jardiance significantly cuts diabetes kidney risk

15 June 2016

Eli Lilly (NYSE:LLY) and Boehringer Ingelheim have revealed new trial data showing that SGLT2 inhibitor Jardiance (empagliflozin) significantly reduces the progression of kidney disease in patients with type 2 diabetes and established cardiovascular (CV) disease.

Results published in the New England Journal of Medicine and also presented at the American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans, show a 39% risk reduction in new-onset or worsening kidney disease in such patients versus placebo, when Jardiance was added to the existing standard of care- renin angiotensin aldosterone system blockade.

Consistent risk reductions in kidney outcomes with once-daily 10 or 25mg doses of Jardiance were seen in adults with impaired kidney function, or increased levels of albumin in the urine, at baseline and in those who did not, according to a post hoc sub-group analysis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK